Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: A case report

Pharmacopsychiatry

Volumn 37, Issue 4, 2004, Pages 189-191

  Bliesener, N ^a   Yokusoglu, H ^a   Quednow, B B ^a   Klingmuller D ^a   Kuhn K U ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BROMOCRIPTINE; PROLACTIN;

ADULT; AMENORRHEA; ARTICLE; BREAST TENDERNESS; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; GALACTORRHEA; HEART PALPITATION; HUMAN; HYPERPROLACTINEMIA; LACTATION; MENSTRUATION; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; BROMOCRIPTINE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; LUTEINIZING HORMONE; MIDDLE AGED; PROLACTIN; PSYCHOTIC DISORDERS; SULPIRIDE;

EID: 3142684620     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-827176     Document Type: Article

References (17)

1. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233-246
2. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205-219
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-123
4. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14: 209-218
5. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35 Suppl: S75-86
6. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 2000; 61 Suppl 3: 10-15
7. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302: 1129-1134
8. Krupp P, Barnes P. Clozapine-associated agranulocytosis, risk and aetiology. Br J Psychiatry 1992; 17 Suppl: 38-40
9. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 Suppl 4: 56-62
10. Marchese G, Ruiu S, Casti P, Bartholini F, Saba P, Gessa GL, Pani L. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. Eur J Pharmacol 2002; 447: 109-114
11. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jpn J Psychiatry Neurol 1986; 40: 639-646
12. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979; 136: 1550-1555
13. Miller KK, Klibanski A. Clinical review 106: Amenorrheic bone loss. J Clin Endocrinol Metab 1999; 84: 1775-1783
14. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 1992; 37: 737-740
15. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000; 23: 765-770
16. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159: 133-135
17. Wetzel H, Wiesner J, Hiemke C, Benkert O. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 1994; 28: 461-473